Order Article Reprints

Ben Khaled N, Hammer K, Ye L, Alnatsha A, Widholz SA, Piseddu I, Sirtl S, Schneider J, Munker S, Mahajan UM, et al. TRAIL Receptor Targeting Agents Potentiate PARP Inhibitor Efficacy in Pancreatic Cancer Independently of BRCA2 Mutation Status. Cancers. 2022; 14(21):5240. https://doi.org/10.3390/cancers14215240

Ben Khaled, Najib, Katharina Hammer, Liangtao Ye, Ahmed Alnatsha, Sebastian A. Widholz, Ignazio Piseddu, Simon Sirtl, Julia Schneider, Stefan Munker, Ujjwal Mukund Mahajan, and et al. 2022. "TRAIL Receptor Targeting Agents Potentiate PARP Inhibitor Efficacy in Pancreatic Cancer Independently of BRCA2 Mutation Status" Cancers 14, no. 21: 5240. https://doi.org/10.3390/cancers14215240

Ben Khaled, N., Hammer, K., Ye, L., Alnatsha, A., Widholz, S. A., Piseddu, I., Sirtl, S., Schneider, J., Munker, S., Mahajan, U. M., Montero, J. J., Griger, J., Mayerle, J., Reiter, F. P., & De Toni, E. N. (2022). TRAIL Receptor Targeting Agents Potentiate PARP Inhibitor Efficacy in Pancreatic Cancer Independently of BRCA2 Mutation Status. Cancers, 14(21), 5240. https://doi.org/10.3390/cancers14215240